Mon October 24th, 2016
Biosimulation is used for target identification & validation, lead discovery & optimization, preclinical testing and clinical trials.
Get FREE PDF Brochure@ http://tinyurl.com/zckn639 The biosimulation market is expected to reach USD 2,107.99 Million by 2020 from USD 1,034.93 Million in 2015, at a CAGR of 15.29%. Biosimulation refers to the modeling and simulation of complex biological processes and systems to understand their functions and physiologies at the molecular level. Biosimulation is used for target identification & validation, lead discovery & optimization, preclinical testing and clinical trials. This market report studies the potential of biosimulation software and services in drug discovery and development. The major drivers for the biosimulation market include the strong trend of R&D investments in biotechnology and pharmaceutical industries; the need to curtail drug discovery & development costs; growth in the biologics and biosimilars market; increased use of personalized medicines; technological advancements; and the trend of periodic product upgradation. Based on geography, the market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). The major players in the global biosimulation market are Certara USA, Inc. (U.S.), Simulation Plus Inc. (U.S.), Dassault Systèmes SA (France), Schrödinger Inc. (U.S.), Advanced Chemistry Development, Inc. (Canada), Chemical Computing Group, Inc. (Canada), Physiomics PLC (U.K.), Entelos Holding Corporation (U.S.), Rhenovia Pharma Ltd. (France), and Genedata AG (Switzerland).